NASDAQ:KURA Kura Oncology (KURA) Stock Price, News & Analysis $21.09 +0.31 (+1.49%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$20.77▼$21.6050-Day Range$19.77▼$23.2352-Week Range$7.41▼$24.17Volume461,781 shsAverage Volume1.06 million shsMarket Capitalization$1.61 billionP/E RatioN/ADividend YieldN/APrice Target$28.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Kura Oncology alerts: Email Address Kura Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside34.5% Upside$28.36 Price TargetShort InterestBearish13.75% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment1.35Based on 2 Articles This WeekInsider TradingSelling Shares$57,922 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.56) to ($2.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.30 out of 5 starsMedical Sector347th out of 936 stocksPharmaceutical Preparations Industry161st out of 436 stocks 3.4 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKura Oncology has only been the subject of 3 research reports in the past 90 days.Read more about Kura Oncology's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.75% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Kura Oncology has recently increased by 1.83%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kura Oncology is -0.76. Previous Next 3.0 News and Social Media Coverage News SentimentKura Oncology has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kura Oncology this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,922.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Kura Oncology is held by insiders.Read more about Kura Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to decrease in the coming year, from ($2.56) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -9.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -9.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kura Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Kura Oncology Stock (NASDAQ:KURA)Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Read More KURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KURA Stock News HeadlinesJuly 26 at 5:45 PM | markets.businessinsider.comBuy Rating for BioAtla: Promising Clinical Assets and Undervaluation Present Investment OpportunityJuly 26 at 7:01 AM | investorplace.comDon't Miss Out: 3 Stocks Poised for a 10X SurgeJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 5, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 24, 2024 | globenewswire.comKura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in DiabetesJune 11, 2024 | businesswire.comLife Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego CommunityJune 7, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2024 | globenewswire.comKura Oncology to Participate in Jefferies Global Healthcare ConferenceJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 25, 2024 | finance.yahoo.comKura Oncology, Inc. (KURA)May 19, 2024 | msn.comInvestor Enthusiasm Soars for Kura Oncology (NASDAQ:KURA)May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amidst Positive Developments and Strong Trial ProgressMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amidst Promising Ziftomenib Trials and Strategic AdvantagesMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)May 14, 2024 | globenewswire.comKura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AMLMay 8, 2024 | globenewswire.comKura Oncology to Participate in Bank of America Securities Healthcare ConferenceMay 7, 2024 | seekingalpha.comKura Oncology: Balancing Act Of Promise And PragmatismMay 6, 2024 | finance.yahoo.comKura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call TranscriptSee More Headlines Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$28.36 High Stock Price Target$37.00 Low Stock Price Target$10.50 Potential Upside/Downside+35.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.52% Return on Assets-34.11% Debt Debt-to-Equity Ratio0.02 Current Ratio16.67 Quick Ratio16.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.35 per share Price / Book3.90Miscellaneous Outstanding Shares76,180,000Free Float71,991,000Market Cap$1.59 billion OptionableOptionable Beta0.88 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Chairman, CEO & President Comp: $1.22MMs. Kathleen Ford (Age 77)Chief Operating Officer Comp: $824.95kMs. Teresa Brophy Bair Esq. (Age 53)J.D., Chief Legal Officer & Corporate Secretary Comp: $705.38kDr. Stephen Dale M.D. (Age 52)Chief Medical Officer Comp: $855.3kMr. Thomas Doyle (Age 53)Senior Vice President of Finance & Accounting Mr. Pete De SpainExecutive Vice President of Investor Relations & Corporate CommunicationsDr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply ChainMs. Maureen Clancy M.B.A.VP and Global Head of Program Leadership & Project ManagementDr. Mollie Leoni M.D.Executive Vice President of Clinical DevelopmentMr. Brian T. Powl M.B.A. (Age 50)M.S., Chief Commercial Officer More ExecutivesKey CompetitorsXencorNASDAQ:XNCRIronwood PharmaceuticalsNASDAQ:IRWDAimmune TherapeuticsNASDAQ:AIMTRa PharmaceuticalsNASDAQ:RARXZymeworksNYSE:ZYMEView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 11,212 shares on 7/26/2024Ownership: 0.336%Aaron Wealth Advisors LLCBought 1,673 shares on 7/22/2024Ownership: 0.092%Hennion & Walsh Asset Management Inc.Sold 54,055 shares on 7/20/2024Ownership: 0.168%Assenagon Asset Management S.A.Bought 577,732 shares on 7/18/2024Ownership: 2.273%Harbor Capital Advisors Inc.Bought 7,899 shares on 7/9/2024Ownership: 0.051%View All Insider TransactionsView All Institutional Transactions KURA Stock Analysis - Frequently Asked Questions How have KURA shares performed this year? Kura Oncology's stock was trading at $14.38 on January 1st, 2024. Since then, KURA shares have increased by 46.7% and is now trading at $21.09. View the best growth stocks for 2024 here. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) issued its earnings results on Thursday, May, 2nd. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.03. The company's quarterly revenue was up .0% compared to the same quarter last year. Who are Kura Oncology's major shareholders? Kura Oncology's top institutional shareholders include Assenagon Asset Management S.A. (2.27%), Bank of New York Mellon Corp (0.34%), Hennion & Walsh Asset Management Inc. (0.17%) and Aaron Wealth Advisors LLC (0.09%). Insiders that own company stock include Thomas Malley, Teresa Brophy Bair, Thomas James Doyle, Kathleen Ford, Kirsten Flowers and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN) and Gilead Sciences (GILD). This page (NASDAQ:KURA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
